ArticleInternational journal of molecular sciences2023
Landscape of
Open access · goldAbstract read
In one paragraph
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective.Blood advances · 2026Review
- When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia.Current hematologic malignancy reports · 2026Review
- Overcoming venetoclax resistance through heme-mediated NOXA/cyclin D1/Mcl-1 axis with a novel artemisinin conjugate.Blood advances · 2025Article
- Structural insights into chemoresistance mutants of BCL-2 and their targeting by stapled BAD BH3 helices.Nature communications · 2025Article
- Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia.Leukemia · 2025Article
- Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy.The Journal of pathology · 2025Article
- Review
- The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy.Signal transduction and targeted therapy · 2025Review
- Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies.Biomarker research · 2024Review
- Review
- BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism.Lymphatics · 2024Article
- Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed.Cancers · 2024Review
- Phenotyping of cancer-associated somatic mutations in the BCL2 transmembrane domain.Oncogenesis · 2024Article
- Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies.Cureus · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 8 institutions in 2 countries.
Lili KotmayerHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.
Tamás LászlóHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0003-3106-9951
Gábor MikalaSouth-Pest Central Hospital, National Institute of Hematology and Infectology, 1097 Budapest, Hungary.ORCID 0000-0003-2204-7398
Richárd KissHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.
Luca LévayHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.
Lajos László HegyiHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.
Stefánia GrófHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.
Tibor NagyHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.
Gábor BarnaHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0002-8895-3062
Péter FarkasDepartment of Internal Medicine and Hematology, Semmelweis University, 1085 Budapest, Hungary.
Júlia WeisingerDepartment of Internal Medicine and Hematology, Semmelweis University, 1085 Budapest, Hungary.
Zsolt NagyDepartment of Internal Medicine and Hematology, Semmelweis University, 1085 Budapest, Hungary.
Alexandra BaloghDepartment of Internal Medicine and Hematology, Semmelweis University, 1085 Budapest, Hungary.
Tamás MassziDepartment of Internal Medicine and Hematology, Semmelweis University, 1085 Budapest, Hungary.
Judit DemeterDepartment of Internal Medicine and Oncology, Semmelweis University, 1085 Budapest, Hungary.
Adrienn Sulák2nd Department of Internal Medicine and Cardiology Center, University of Szeged, 6725 Szeged, Hungary.
Zoltán Kohl1st Department of Internal Medicine, Clinical Centre, University of Pécs, 7622 Pécs, Hungary.
Hussain Alizadeh1st Department of Internal Medicine, Clinical Centre, University of Pécs, 7622 Pécs, Hungary.
Miklós EgyedKaposi Mór University Teaching Hospital of County Somogy, 7400 Kaposvár, Hungary.
Piroska PettendiHetényi Géza Hospital, Clinic of County Jász-Nagykun-Szolnok, 5000 Szolnok, Hungary.
Lajos GergelyDivision of Hematology, Department of Internal Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Márk PlanderMarkusovszky University Teaching Hospital, 9700 Szombathely, Hungary.
Zsolt PaukerBorsod-Abaúj-Zemplén County Hospital and University Teaching Hospital, 3515 Miskolc, Hungary.
András MassziNational Institute of Oncology, 1122 Budapest, Hungary.
András MatolcsyHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.
Róbert SzászDivision of Hematology, Department of Internal Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Csaba BödörHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0002-0729-692X
Donát AlpárHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0002-2638-5418
Semmelweis University · HUUniversity of Debrecen · HUUniversity of Pecs · HUBorsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház · HUMarkusovszky Egyetemi Oktatókórház · HUNational Institute of Oncology · HUSomogy Megyei Kaposi Mór Oktató Kórház · HUUniversity of Szeged · HU
Funding
ELIXIR Hungary ELIXIR HungaryEU Horizon 739593Hungarian Academy of Sciences BO/00125/22Ministry for Innovation and Technology ÚNKP-22-5-SE-7National Research, Development and Innovation Office FK20_134253National Research, Development and Innovation Office K21_137948Semmelweis University EFOP-3.6.3-VEKOP-16-2017-00009
Abstract
The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic
Indexed as
Antineoplastic AgentsLeukemia, Lymphocytic, Chronic, B-CellAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicDisease ProgressionDrug Resistance, NeoplasmHumansMutationProto-Oncogene Proteins c-bcl-2RecurrenceSulfonamidesAntineoplastic AgentsBCL2 protein, humanBridged Bicyclo Compounds, HeterocyclicProto-Oncogene Proteins c-bcl-2SulfonamidesvenetoclaxBCL2CLLmolecular monitoringtherapy resistancevenetoclax
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.